FGF23 induces left ventricular hypertrophy

Chronic kidney disease (CKD) is a public health epidemic that increases risk of death due to cardiovascular disease. Left ventricular hypertrophy (LVH) is an important mechanism of cardiovascular disease in individuals with CKD. Elevated levels of FGF23 have been linked to greater risks of LVH and mortality in patients with CKD, but whether these risks represent causal effects of FGF23 is unknown. Here, we report that elevated FGF23 levels are independently associated with LVH in a large, racially diverse CKD cohort. FGF23 caused pathological hypertrophy of isolated rat cardiomyocytes via FGF receptor-dependent activation of the calcineurin-NFAT signaling pathway, but this effect was independent of klotho, the…

• UD
  U.S. Department of Veterans Affairs
• AH
  American Heart Association
• AL
  Abbott Laboratories
• A
  Amgen
• NF
  Nephcure Foundation
• UO
  University of Miami
• UO
  University of Pennsylvania
• HS
  Health Services Research and Development
• CC
  Cleveland Clinic
• CC
  Cleveland Clinic Foundation
• JH
  Johns Hopkins University

  Award: RR025005
• UO
  University of Texas Southwestern Medical Center
• CW
  Case Western Reserve University

  Award: UL1 RR024989
• DK
  Deutsches Krebsforschungszentrum
• MO
  Ministry of Education, India
• S
  Stifterverband
• NI
  National Institutes of Health

  Awards: R01DK076116, M01 RR-000042, RR05096, UL1 RR024986, RR025005, RR024989, RR024131, UL1 RR024134, R01DK081374, UL1 RR025005, UL1 RR024989, R01DK091392
• UO
  University of Illinois at Urbana-Champaign
• UO
  University of California, San Francisco
• LM
  Leonard M. Miller School of Medicine
• NI
  National Institute of Diabetes and Digestive and Kidney Diseases

  Awards: R01DK081374, 5U01DK06102, 5U01DK060984, 5U01DK60980, R01DK076116, 5U01DK060990, 5U01DK061028, RR024986, UL1 RR024986, UL1 RR024134, 5U01DK061021, 5U01DK060902, 5U01DK060963